Solitomab
Solitomab (pronunciation: so-li-to-mab) is a bi-specific T-cell engager (BiTE) antibody used for the treatment of various types of cancer. It is designed to direct the body's cell-destroying T cells against cancer cells.
Etymology
The term "Solitomab" is derived from Latin roots. "Soli-" comes from "solus" meaning "alone" or "only", and "-mab" is an abbreviation for "monoclonal antibody", a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
Mechanism of Action
Solitomab works by binding to two different types of cells at the same time: the CD3 protein found on T cells and the EpCAM protein found on cancer cells. This dual binding action allows the T cells to recognize and kill the cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Bi-specific T-cell Engager (BiTE): A type of immunotherapy that helps the immune system to target cancer cells.
- T cells: A type of white blood cell that is of key importance to the immune system and is at the core of adaptive immunity, the system that tailors the body's immune response to specific pathogens.
- CD3: A protein complex and T cell co-receptor that is involved in activating both the cytotoxic T-Cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
- EpCAM: An antigen that is expressed on the surface of most epithelial cancer cells and is a potential target for antibody-based cancer immunotherapy.
See Also
External links
- Medical encyclopedia article on Solitomab
- Wikipedia's article - Solitomab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski